| P50 | author | Pratika Y Hernanda | Q85267879 |
| | Maikel P Peppelenbosch | Q51363232 |
| | Wichor M. Bramer | Q35703475 |
| | Qiuwei Pan | Q39066373 |
| P2093 | author name string | Juan Li | |
| | Judith van Luijk | |
| P2860 | cites work | Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation | Q83247914 |
| | Metformin inhibits growth of hepatocellular carcinoma cells by inducing apoptosis via mitochondrion-mediated pathway. | Q39275139 |
| | Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies | Q39317976 |
| | Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. | Q39340562 |
| | Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. | Q39370938 |
| | Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice | Q42250436 |
| | Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma | Q42276934 |
| | Preventive effect of Metformin against N-nitrosodiethylamine-initiated hepatocellular carcinoma in rats | Q42557069 |
| | Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis. | Q45909685 |
| | In vitro and in vivo antitumoral action of metformin on hepatocellular carcinoma | Q46473638 |
| | Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo. | Q51786739 |
| | Role of AMP-activated protein kinase in mechanism of metformin action | Q22241898 |
| | The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress | Q24633606 |
| | Sorafenib in advanced hepatocellular carcinoma | Q27861075 |
| | Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells | Q28534922 |
| | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 |
| | AMP-activated protein kinase suppresses the in vitro and in vivo proliferation of hepatocellular carcinoma | Q31158130 |
| | Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical t | Q34023560 |
| | SYRCLE's risk of bias tool for animal studies | Q35130894 |
| | The Effect of Metformin Treatment on CRBP-I Level and Cancer Development in the Liver of HBx Transgenic Mice | Q37297707 |
| | Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis | Q38079130 |
| | Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation | Q38174585 |
| | Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo | Q38997403 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metformin | Q19484 |
| | liver neoplasm | Q18558073 |
| | systematic review | Q1504425 |
| | hepatocellular carcinoma | Q1148337 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | e0127967 | |
| P577 | publication date | 2015-06-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Anti-tumor effects of metformin in animal models of hepatocellular carcinoma: a systematic review and meta-analysis | |
| P478 | volume | 10 | |